Gyre Therapeutics, Inc.

GYRE · Nasdaq · ·

Karşılaştır

$4,30-%0,213 Kas kapanış

30 Eylül 2026 tarihine kadarki rakamlar, 6 Kasım 2026 tarihinde sunulan 10-Q raporundan

1W: -%9,7
1M: -%32,8

Just reported

Q3 2026 results

From Gyre Therapeutics's results release of 5 Kasım 2026; its quarterly report has since been filed.

Revenue
Actual
$32,9M
+%0,7 y/y
+%13 q/q
Guided
—
No guide given
EPS, GAAP
Actual
-$0,04
Guided
—
No guide given
Operating income, GAAP
Actual
-$1,5M
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$100,5M – $111M-%9,3 y/y Unchanged

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Gyre Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 352 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Tüm finansal tablolar →

Gyre Therapeutics, Inc. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

Q3 2026 results

Revenue

EPS, GAAP